Global Cancer Biomarker Market Research Report - Forecast to 2023
SKU ID :MRF-11586514 | Published Date: 05-Feb-2018 | No. of pages: 144Description
TOC
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6 Global Cancer Biomarker Market, By Types
6.1 Introduction
6.2 Protein Biomarker
6.3 Genetic Biomarker
6.4 Others
Chapter 7 Global Cancer Biomarker Market, By Application
7.1 Introduction
7.2 Diagnostic
7.2.1 Imaging
7.2.2 Non- Imaging
7.3 Prognostic
7.4 Therapeutic
Chapter 8 Global Cancer Biomarker Market, By End Users
8.1 Introduction
8.2 Pharma & Biotech Companies
8.3 Diagnostic Tool Companies
8.4 Healthcare IT/Big Data Companies
8.5 Clinical Laboratories
Chapter 9. Global Cancer Biomarker Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Becton Dickinson
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 PerkinElmer, Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Bristol-Myers Squibb
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Bio-Rad Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Eli Lilly and Company
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Merck & Co., Inc
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Pfizer Inc.
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.10 GlaxoSmithKline plc.
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 QIAGEN N.V
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
11.12 Novartis AG
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
11.13 Thermo Fisher Scientific Inc.
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Strategy
11.13.5 Key Developments
11.14 Illumina Inc.
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Strategy
11.14.5 Key Developments
11.15 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Medical End Users Industry
Chapter 13 Appendix
Tables & Figures
List of Tables:
Table 1 Cancer Biomarker Industry Synopsis, 2017 – 2023
Table 2 Global Cancer Biomarker Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Cancer Biomarker Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 5 Global Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 6 Global Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 8 North America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 9 North America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 11 US Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 12 US Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Market by Type, 2017 – 2023, (USD Million)
Table 14 Canada Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 15 Canada Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 17 South America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 18 South America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 20 Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 21 Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 23 Western Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 24 Western Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)
List of Figures:
Figure 1 Research Process
Figure 2 Segmentation for Global Cancer Biomarker Market
Figure 3 Segmentation Market Dynamics for Global Cancer Biomarker Market
Figure 4 Global Cancer Biomarker market Share, by Type 2016
Figure 5 Global Cancer Biomarker market Share, by Application 2016
Figure 6 Global Cancer Biomarker Market Share, by End Users, 2016
Figure 7 Global Cancer Biomarker Market Share, by Region, 2016
Figure 8 North America Cancer Biomarker Market Share, by Country, 2016
Figure 9 Europe Cancer Biomarker Market Share, by Country, 2016
Figure 10 Asia Pacific Cancer Biomarker Market Share, by Country, 2016
Figure 11 Middle East & Africa Cancer Biomarker Market Share, by Country, 2016
Figure 12 Global Cancer Biomarker Market: Company Share Analysis, 2016 (%)
Figure 13 F. Hoffmann-La Roche AG: Key Financials
Figure 14 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 15 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 16 Becton Dickinson: Key Financials
Figure 17 Becton Dickinson: Segmental Revenue
Figure 18 Becton Dickinson: Geographical Revenue
Figure 19 Abbott Laboratories: Key Financials
Figure 20 Abbott Laboratories: Segmental Revenue
Figure 21 Abbott Laboratories: Geographical Revenue
Figure 22 PerkinElmer, Inc.: Key Financials
Figure 23 PerkinElmer, Inc.: Segmental Revenue
Figure 24 PerkinElmer, Inc.: Geographical Revenue
Figure 25 Bristol-Myers Squibb: Key Financials
Figure 26 Bristol-Myers Squibb: Segmental Revenue
Figure 27 Bristol-Myers Squibb: Geographical Revenue
Figure 28 Bio-Rad Laboratories: Key Financials
Figure 29 Bio-Rad Laboratories: Segmental Revenue
Figure 30 Bio-Rad Laboratories: Geographical Revenue
Figure 31 Bio-Rad Laboratories: Key Financials
Figure 33 F. Hoffmann-La Roche AG: Key Financials
Figure 34 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 35 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 36 Becton Dickinson: Key Financials
Figure 37 Becton Dickinson: Segmental Revenue
Figure 38 Becton Dickinson: Geographical Revenue
Figure 39 Abbott Laboratories: Key Financials
Figure 40 Abbott Laboratories: Segmental Revenue
Figure 41 Abbott Laboratories: Geographical Revenue
Figure 42 PerkinElmer, Inc.: Key Financials
Figure 43 PerkinElmer, Inc.: Segmental Revenue
Figure 44 PerkinElmer, Inc.: Geographical Revenue
Figure 45 Bristol-Myers Squibb: Key Financials
Figure 46 Bristol-Myers Squibb: Segmental Revenue
Figure 47 Bristol-Myers Squibb: Geographical Revenue
Figure 48 Bio-Rad Laboratories: Key Financials
Figure 49 Bio-Rad Laboratories: Segmental Revenue
Figure 50 Bio-Rad Laboratories: Geographical Revenue
Figure 51 Eli Lilly and Company: Key Financials
Figure 52 Eli Lilly and Company: Segmental Revenue
Figure 53 Eli Lilly and Company: Geographical Revenue
Figure 54 Merck & Co., Inc.: Key Financials
Figure 55 Merck & Co., Inc.: Segmental Revenue
Figure 56 Merck & Co., Inc.: Geographical Revenue
Figure 57 Pfizer Inc.: Key Financials
Figure 58 Pfizer Inc.: Segmental Revenue
Figure 59 Pfizer Inc.: Geographical Revenue
Figure 60 GlaxoSmithKline plc: Key Financials
Figure 61 GlaxoSmithKline plc: Segmental Revenue
Figure 62 GlaxoSmithKline plc: Geographical Revenue
Figure 63 QIAGEN N.V: Key Financials
Figure 64 QIAGEN N.V: Segmental Revenue
Figure 65 QIAGEN N.V: Geographical Revenue
Figure 66 Novartis AG: Key Financials
Figure 67 Novartis AG: Segmental Revenue
Figure 68 Novartis AG: Geographical Revenue
Figure 69 Thermo Fisher Scientific Inc.: Key Financials
Figure 70 Thermo Fisher Scientific Inc.: Segmental Revenue
Figure 71 Thermo Fisher Scientific Inc.: Geographical Revenue
Figure 72 Illumina Inc.: Key Financials
Figure 73 Illumina Inc.: Segmental Revenue
Figure 74 Illumina Inc.: Geographical Revenue
Companies
F. Hoffmann-La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Merck & Co., Inc.(U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), PerkinElmer, Inc (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc (U.S.), QIAGEN N.V (Germany), Thermo Fisher Scientific Inc (U.S.), Illumina Inc (U.S.), and others.
- PRICE
-
$4450$6250